Innova Captab IPO Analysis @ Chanakyanipothi.com,
India`s Oldest & the most Trusted Investment website. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.

Innova Captab IPO Promoters
MANOJ KUMAR LOHARIWALA AND VINAY KUMAR LOHARIWALA

 Very Elaborate Business Information of Innova Captab

Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Its business includes (i) a contract development and manufacturing organization (“CDMO”) business providing manufacturing services to Indian pharmaceutical companies, (ii) a domestic branded generics business and (iii) an international branded generics business. In terms of operating revenue, it was the second largest formulation CDMO in India in Fiscal 2021 and the third fastest growing formulation CDMO over the period Fiscal 2019 to Fiscal 2021. In the nine months ended December 31, 2021, it has 164 CDMO customers. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2021 have been a part of its customer base. It manufactures its diverse generics product portfolio of over 400 products and market them under its own brands in the Indian market through a developed network of approximately 3,400 distributors and stockists and over 96,000 retail pharmacies. In addition, during the nine months ended December 31, 2021, it exported its branded generic products to 17 countries. Its CDMO services and products include commercial large-scale manufacturing of generic products. It also enters into loan license agreements with its customers. In its CDMO business, it has developed relationships across the Indian pharmaceutical industry.

Some of its key customers include Cipla Limited, Glenmark Pharmaceuticals Limited, Wockhardt Limited, Corona Remedies Private Limited, Emcure Pharmaceuticals Limited, Lupin Limited, Intas Pharmaceuticals Limited, Leeford Healthcare Limited, Medley Pharmaceuticals Limited, Cachet Pharmaceuticals Limited, Eris Healthcare Private Limited, Indoco Remedies Limited, J. B. Chemicals and Pharmaceuticals Limited, Oaknet Healthcare Private Limited, Zuventus Healthcare Limited, Ajanta Pharma Limited, Mankind Pharma Limited and Smart Laboratories Private Limited. Revenue from its CDMO business on a restated consolidated basis has grown at a 5.79% CAGR from Rs. 3,313.68 million in Fiscal 2019 to Rs.3,708.71 million in Fiscal 2021
Qualitative Factors
• leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market.
• well established relationships with our marquee CDMO customer base
• highly efficient operations, including our world class manufacturing facilities and supply chain
• rapidly growing domestic and international export branded generics businesses
• strong R&D focus to build an increasingly complex product portfolio and attract and retain customers
• consistent financial performance; and
• experienced promoters and management team.
For more information, click www.innovacaptab.com

Objects of the IPO
The Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding:
1. Repayment and / or prepayment in part or in full of certain outstanding loans of the Company.
2. Investment in its Subsidiary, UML, for repayment and / or prepayment in part or full of an outstanding
loan availed by UML.
3. Funding its working capital requirements.

Go to SME IPOs Section: Click